phosphatidylcholines has been researched along with Sclerosis, Systemic in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katayama, I; Mizushima, Y; Nishioka, K; Takagawa, S; Yamamoto, T | 1 |
| Ioannidis, JP; Moutsopoulos, HM; Petrovas, CA; Tektonidou, MG; Vlachoyiannopoulos, PG | 1 |
2 other study(ies) available for phosphatidylcholines and Sclerosis, Systemic
| Article | Year |
|---|---|
Effect of superoxide dismutase on bleomycin-induced dermal sclerosis: implications for the treatment of systemic sclerosis.
Topics: Animals; Bleomycin; Disease Models, Animal; Hydroxyproline; Injections, Intravenous; Mannitol; Mice; Mice, Inbred BALB C; Mice, Inbred C3H; Phosphatidylcholines; Scleroderma, Localized; Scleroderma, Systemic; Skin; Superoxide Dismutase | 1999 |
Clinical importance of antibodies against platelet activating factor in antiphospholipid syndrome manifestations.
Topics: Adult; Aged; Antibodies, Anticardiolipin; Antibody Specificity; Antiphospholipid Syndrome; beta 2-Glycoprotein I; Enzyme-Linked Immunosorbent Assay; Female; Glycoproteins; Humans; Immunoglobulin G; Immunoglobulin M; Male; Middle Aged; Odds Ratio; Phosphatidylcholines; Platelet Activating Factor; Scleroderma, Systemic; Seroepidemiologic Studies; Thrombosis | 2000 |